Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Cash Flow (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Net Cash Flow data on record, last reported at $5.1 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 131.9% year-over-year to $5.1 million; the TTM value through Dec 2025 reached -$100.7 million, down 215.78%, while the annual FY2025 figure was -$100.7 million, 215.78% down from the prior year.
  • Net Cash Flow reached $5.1 million in Q4 2025 per TGTX's latest filing, up from -$55.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $112.9 million in Q3 2024 and bottomed at -$113.2 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$23.7 million, with a median of -$32.4 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: plummeted 1083.02% in 2021, then skyrocketed 244.84% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$27.6 million in 2021, then soared by 72.66% to -$7.6 million in 2022, then crashed by 667.56% to -$58.0 million in 2023, then soared by 72.53% to -$15.9 million in 2024, then surged by 131.9% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $5.1 million in Q4 2025, -$55.0 million in Q3 2025, and -$3.0 million in Q2 2025.